Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free ADMA Stock Alerts

ADMA Biologics (ADMA) Financials

ADMA Biologics logo
$8.50 +0.29 (+3.53%)
Closing price 04:00 PM Eastern
Extended Trading
$8.46 -0.04 (-0.47%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ADMA Biologics

Annual Income Statements for ADMA Biologics

This table shows ADMA Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -20 -44 -66 -48 -76 -72 -66 -28 198 147
Consolidated Net Income / (Loss)		 -18 -20 -44 -66 -48 -76 -72 -66 -28 198 147
Net Income / (Loss) Continuing Operations		 -18 -20 -44 -66 -48 -76 -72 -66 -28 198 147
Total Pre-Tax Income 		-18 -20 -44 -66 -48 -76 -72 -66 -28 126 183
Total Operating Income		 -16 -17 -39 -60 -41 -65 -58 -39 22 139 191
Total Gross Profit		 2.87 4.30 -6.40 -25 -10 -19 1.17 35 89 220 293
Total Revenue		 7.18 11 23 17 29 42 81 154 258 426 510
Operating Revenue		 7.18 11 23 17 29 42 81 154 258 426 510
Total Cost of Revenue		 4.31 6.36 29 42 40 61 80 119 169 207 217
Operating Cost of Revenue		 4.31 6.36 29 42 40 61 80 119 169 207 217
Total Operating Expenses		 18 22 33 35 31 46 60 75 67 81 101
Selling, General & Admin Expense		 11 14 25 30 28 39 55 70 63 78 96
Research & Development Expense		 7.02 7.69 5.57 3.93 2.34 5.91 3.65 3.61 3.30 1.81 4.76
Amortization Expense		 - 0.00 1.23 0.84 0.84 0.72 0.72 0.72 0.72 0.39 0.14
Total Other Income / (Expense), net		 -2.46 -2.18 -4.45 -5.45 -6.85 -11 -13 -27 -50 -13 -8.79
Interest Expense		 2.56 2.24 4.50 5.52 19 11 13 26 51 15 10
Interest & Investment Income		 0.04 0.05 0.06 0.20 0.80 0.29 0.04 0.05 1.62 2.10 1.87
Other Income / (Expense), net		 0.07 0.00 -0.01 -0.13 11 -0.13 -0.25 -0.64 -0.29 -0.19 -0.21
Income Tax Expense		 - - - - - - - 0.00 0.00 -72 36
Basic Earnings per Share		 ($1.73) ($1.61) ($1.91) ($1.45) ($0.89) ($0.88) ($0.51) ($0.33) ($0.13) $0.85 $0.62
Weighted Average Basic Shares Outstanding		 10.41M 12.15M 22.90M 45.19M 54.35M 86.15M 139.58M 197.87M 223.98M 233.08M 238.30M
Diluted Earnings per Share		 ($1.73) ($1.61) ($1.91) ($1.45) ($0.89) ($0.88) ($0.51) ($0.33) ($0.13) $0.81 $0.60
Weighted Average Diluted Shares Outstanding		 10.41M 12.15M 22.90M 45.19M 54.35M 86.15M 139.58M 197.87M 223.98M 243.34M 244.90M

Quarterly Income Statements for ADMA Biologics

This table shows ADMA Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.57 -18 18 32 36 112 27 34 36 49 45
Consolidated Net Income / (Loss)		 2.57 -18 18 32 36 112 27 34 36 49 45
Net Income / (Loss) Continuing Operations		 2.57 -18 18 32 36 112 27 34 36 49 45
Total Pre-Tax Income 		2.57 -18 18 36 37 35 33 40 48 62 57
Total Operating Income		 8.69 14 22 39 40 38 35 43 51 63 58
Total Gross Profit		 25 31 39 57 60 63 61 67 76 89 81
Total Revenue		 67 74 82 107 120 118 115 122 134 139 114
Operating Revenue		 67 74 82 107 120 118 115 122 134 139 114
Total Cost of Revenue		 43 43 43 50 60 54 54 55 59 50 34
Operating Cost of Revenue		 43 43 43 50 60 54 54 55 59 50 34
Total Operating Expenses		 16 17 17 18 20 25 26 24 25 26 30
Selling, General & Admin Expense		 15 16 17 18 20 25 25 23 23 25 28
Research & Development Expense		 0.60 0.45 0.45 0.56 0.41 0.39 0.83 1.03 1.53 1.38 2.60
Amortization Expense		 0.18 0.19 0.19 0.14 0.03 0.03 0.03 0.03 0.04 0.05 0.06
Total Other Income / (Expense), net		 -6.12 -32 -3.42 -3.35 -2.89 -3.61 -1.43 -2.70 -3.50 -1.16 6.83
Interest Expense		 6.40 32 3.77 3.78 3.50 4.12 1.98 2.99 3.85 1.63 2.10
Interest & Investment Income		 0.42 0.61 0.38 0.45 0.67 0.60 0.61 0.40 0.38 0.49 9.07
Other Income / (Expense), net		 -0.15 -0.10 -0.04 -0.02 -0.06 -0.09 -0.06 -0.11 -0.02 -0.02 -0.14
Income Tax Expense		 0.00 - 0.60 3.79 0.84 -77 6.55 5.88 11 12 12
Basic Earnings per Share		 $0.01 ($0.08) $0.08 $0.14 $0.15 $0.48 $0.11 $0.14 $0.15 $0.22 $0.19
Weighted Average Basic Shares Outstanding		 225.28M 223.98M 228.87M 232.42M 234.57M 233.08M 237.78M 241.49M 238.60M 238.30M 236.07M
Diluted Earnings per Share		 $0.01 ($0.08) $0.08 $0.13 $0.15 $0.45 $0.11 $0.14 $0.15 $0.20 $0.19
Weighted Average Diluted Shares Outstanding		 233.76M 223.98M 236.41M 242.17M 244.80M 243.34M 244.68M 248.61M 244.66M 244.90M 239.96M
Weighted Average Basic & Diluted Shares Outstanding		 225.97M 228.22M 231.81M 233.08M 236.39M 237.62M - - - 0.00 231.77M

Annual Cash Flow Statements for ADMA Biologics

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -6.76 -0.53 39 -22 -0.00 29 -4.83 35 -35 52 -16
Net Cash From Operating Activities		 -15 -18 -37 -63 -76 -102 -112 -60 8.80 119 50
Net Cash From Continuing Operating Activities		 -15 -18 -37 -63 9.71 -102 -112 -60 8.80 119 50
Net Income / (Loss) Continuing Operations		 -18 -20 -44 -66 -48 -76 -72 -66 -28 198 147
Consolidated Net Income / (Loss)		 -18 -20 -44 -66 -48 -76 -72 -66 -28 198 147
Depreciation Expense		 0.47 0.47 2.69 3.45 3.26 3.94 5.50 7.11 8.33 8.05 8.10
Amortization Expense		 0.27 0.53 0.64 0.96 1.04 1.64 1.75 2.26 2.45 0.81 0.57
Non-Cash Adjustments To Reconcile Net Income		 2.55 1.25 3.44 2.35 12 1.95 3.71 15 36 15 23
Changes in Operating Assets and Liabilities, net		 -0.74 -1.01 -0.28 -3.69 41 -34 -52 -18 -10 -103 -129
Net Cash From Investing Activities		 -1.74 0.90 15 -2.10 -3.81 -13 -14 -14 -4.98 -8.58 -22
Net Cash From Continuing Investing Activities		 -1.74 0.90 15 -2.10 -3.81 -13 -14 -14 -4.98 -8.58 -22
Purchase of Property, Plant & Equipment		 -0.03 -0.07 -2.68 -2.10 -3.81 -13 -14 -14 -4.77 -8.23 -23
Acquisitions		 - 0.00 - - - - 0.00 0.00 -0.21 -0.35 -0.32
Other Investing Activities, net		 - - - - - - - - - - 1.00
Net Cash From Financing Activities		 10 17 61 43 80 144 121 109 -39 -58 -44
Net Cash From Continuing Financing Activities		 10 17 61 43 80 144 121 109 -39 -58 -44
Repayment of Debt		 -16 -0.06 -22 0.00 -32 -15 0.00 -105 -172 -60 -109
Repurchase of Common Equity		 0.00 - - - - - - - 0.00 0.00 -32
Issuance of Debt		 - 4.00 45 0.04 73 28 0.00 152 135 0.00 105
Other Financing Activities, net		 16 0.00 -1.78 0.01 -9.21 -0.02 -0.10 -2.76 -1.91 2.15 -7.88

Quarterly Cash Flow Statements for ADMA Biologics

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 -23 -6.03 43 -1.54 16 -32 19 -29 26 51
Net Cash From Operating Activities		 12 18 -2.22 46 25 50 -20 21 13 36 58
Net Cash From Continuing Operating Activities		 12 18 -2.22 46 25 50 -20 21 13 36 58
Net Income / (Loss) Continuing Operations		 2.57 -18 18 32 36 112 27 34 36 49 45
Consolidated Net Income / (Loss)		 2.57 -18 18 32 36 112 27 34 36 49 45
Depreciation Expense		 2.09 2.11 2.11 2.05 1.94 1.94 1.97 2.06 2.02 2.05 1.84
Amortization Expense		 0.69 0.66 0.22 0.19 0.22 0.18 0.15 0.13 0.13 0.16 0.16
Non-Cash Adjustments To Reconcile Net Income		 2.78 29 2.16 2.86 3.19 6.75 4.62 6.12 7.22 5.40 -1.61
Changes in Operating Assets and Liabilities, net		 3.86 3.60 -25 8.48 -16 -71 -53 -21 -33 -21 13
Net Cash From Investing Activities		 -0.76 -1.41 -2.36 -2.37 -1.10 -2.75 -4.72 -2.53 -14 -0.28 2.40
Net Cash From Continuing Investing Activities		 -0.76 -1.41 -2.36 -2.37 -1.10 -2.75 -4.72 -2.53 -14 -0.28 2.40
Purchase of Property, Plant & Equipment		 -0.76 -1.20 -2.35 -2.07 -1.06 -2.76 -4.70 -2.42 -14 -1.08 -2.54
Acquisitions		 - -0.21 -0.02 -0.30 -0.04 0.01 -0.02 -0.11 - -0.19 -0.05
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 5.00
Net Cash From Financing Activities		 0.42 -39 -1.45 -0.36 -25 -31 -7.13 0.05 -28 -9.12 -10
Net Cash From Continuing Financing Activities		 0.42 -39 -1.45 -0.36 -25 -31 -7.13 0.05 -28 -9.12 -10
Repayment of Debt		 - -172 - - - -30 0.00 - -78 -0.48 -0.47
Repurchase of Common Equity		 - - - - - - 0.00 - - -8.90 -130
Issuance of Debt		 - - - - - - 0.00 - 75 - 125
Other Financing Activities, net		 0.42 -1.92 -1.45 -0.36 4.53 -0.58 -7.13 0.50 -1.51 0.27 -4.47

Annual Balance Sheets for ADMA Biologics

This table presents ADMA Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 24 24 108 89 127 208 276 348 329 489 624
Total Current Assets		 21 22 62 45 86 154 209 270 257 331 467
Cash & Equivalents		 10 9.91 43 23 27 56 51 87 51 103 88
Accounts Receivable		 0.92 1.02 3.88 1.39 3.47 13 29 16 27 50 158
Inventories, net		 3.45 5.02 13 19 53 82 125 163 173 170 206
Prepaid Expenses		 0.11 0.31 1.23 1.77 2.53 3.05 4.34 5.10 5.33 8.03 7.46
Other Current Assets		 - - - - - - - - - 0.00 6.53
Plant, Property, & Equipment, net		 2.40 2.00 30 30 32 42 51 58 54 55 65
Total Noncurrent Assets		 0.03 0.03 15 14 9.53 12 17 20 18 103 93
Goodwill		 - 0.00 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53
Intangible Assets		 - 0.00 4.85 4.00 3.16 2.44 1.73 1.01 0.50 0.46 0.63
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 0.00 84 73
Other Noncurrent Operating Assets		 0.03 0.03 6.83 6.70 2.84 6.37 11 15 14 14 15
Total Liabilities & Shareholders' Equity		 24 24 108 89 127 208 276 348 329 489 624
Total Liabilities		 23 28 68 69 101 119 135 196 194 140 147
Total Current Liabilities		 4.22 11 9.44 9.63 14 20 30 39 50 56 70
Short-Term Debt		 0.02 6.11 0.00 0.03 - - - - - 0.00 2.81
Accounts Payable		 2.09 2.56 5.92 5.90 9.17 11 12 13 16 20 23
Accrued Expenses		 1.97 2.39 3.38 3.55 4.48 8.37 17 25 33 34 40
Other Current Liabilities		 - 0.02 - - 0.23 0.37 0.59 0.91 1.05 1.22 1.10
Other Current Nonoperating Liabilities		 - - - - - - - - - 0.00 2.65
Total Noncurrent Liabilities		 19 17 58 59 87 99 105 157 144 84 77
Long-Term Debt		 14 14 43 44 83 93 95 143 131 72 69
Capital Lease Obligations		 0.04 - 0.00 0.12 1.30 4.33 7.46 11 9.78 8.56 6.65
Noncurrent Deferred Revenue		 2.96 2.69 2.55 2.40 2.26 2.12 1.98 1.83 1.69 1.55 1.41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.82 -4.46 40 20 26 88 141 152 135 349 477
Total Preferred & Common Equity		 0.82 -4.46 40 20 26 88 141 152 135 349 477
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.82 -4.46 40 20 26 88 141 152 135 349 477
Common Stock		 88 102 191 236 291 429 553 630 641 658 671
Retained Earnings		 -87 -107 -151 -216 -265 -340 -412 -478 -506 -309 -162
Treasury Stock		 - - - - - - - - - 0.00 -32

Quarterly Balance Sheets for ADMA Biologics

This table presents ADMA Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 301 341 343 349 351 376 391 511 558 569 665
Total Current Assets		 224 264 266 274 276 304 318 352 400 403 511
Cash & Equivalents		 35 69 63 74 45 88 87 72 90 61 138
Accounts Receivable		 21 27 37 31 50 30 50 99 110 138 136
Inventories, net		 163 164 162 163 178 180 172 172 191 197 222
Prepaid Expenses		 5.37 4.38 5.22 5.11 3.74 5.52 9.55 8.59 8.09 6.93 15
Other Current Assets		 - - - - - - - - - - 0.00
Plant, Property, & Equipment, net		 57 57 56 55 55 54 54 58 58 70 65
Total Noncurrent Assets		 20 19 20 20 19 18 19 101 101 97 89
Goodwill		 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53 3.53
Intangible Assets		 1.19 0.83 0.66 0.48 0.32 0.48 0.49 0.45 0.53 0.49 0.63
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - 81 79 74 70
Other Noncurrent Operating Assets		 15 15 16 16 15 14 15 16 18 18 15
Total Liabilities & Shareholders' Equity		 301 341 343 349 351 376 391 511 558 569 665
Total Liabilities		 200 195 196 198 197 188 159 137 160 138 275
Total Current Liabilities		 44 37 42 42 53 44 45 53 75 56 74
Short-Term Debt		 - - - - - - - - - 2.34 3.28
Accounts Payable		 25 13 12 11 17 14 16 21 30 24 21
Accrued Expenses		 18 23 29 30 34 28 28 32 44 29 49
Other Current Liabilities		 0.72 0.96 0.98 0.98 1.09 1.14 1.19 1.19 1.13 1.30 1.18
Other Current Nonoperating Liabilities		 - - - - - - - - - - 0.00
Total Noncurrent Liabilities		 156 158 154 156 144 144 114 84 85 81 201
Long-Term Debt		 141 144 140 142 131 131 101 73 73 70 194
Capital Lease Obligations		 11 10 10 9.97 9.49 9.18 8.87 8.30 9.30 9.40 6.37
Noncurrent Deferred Revenue		 1.87 1.80 1.76 1.73 1.65 1.62 1.58 1.51 1.48 1.44 1.37
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 100 146 147 151 154 188 232 373 398 431 390
Total Preferred & Common Equity		 100 146 147 151 154 188 232 373 398 431 390
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 100 146 147 151 154 188 232 373 398 431 390
Common Stock		 566 630 638 640 642 645 652 655 661 665 650
Retained Earnings		 -466 -485 -491 -489 -488 -456 -420 -282 -247 -211 -116
Treasury Stock		 - - - - - - - - -15 -23 -143

Annual Metrics And Ratios for ADMA Biologics

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 21.34% 48.53% 113.49% -25.37% 72.79% 43.85% 91.72% 90.36% 67.59% 65.15% 19.63%
EBITDA Growth		 6.08% -10.96% -120.49% -55.63% 53.88% -130.22% 13.60% 40.38% 204.90% 359.55% 35.39%
EBIT Growth		 4.02% -12.17% -126.94% -53.65% 50.14% -115.92% 9.87% 31.77% 153.36% 550.22% 37.78%
NOPAT Growth		 3.15% -11.71% -126.83% -53.37% 31.29% -56.71% 10.08% 32.56% 154.95% 1,343.21% -29.53%
Net Income Growth		 -6.88% -8.60% -124.23% -50.24% 26.56% -56.90% 5.41% 8.02% 57.15% 800.00% -25.67%
EPS Growth		 4.42% 6.94% -18.63% 24.08% 38.62% 1.12% 42.05% 35.29% 60.61% 723.08% -25.93%
Operating Cash Flow Growth		 -4.85% -18.49% -104.02% -68.17% -21.56% -33.87% -10.16% 47.04% 114.79% 1,248.55% -57.53%
Free Cash Flow Firm Growth		 18.72% -39.00% -360.41% 31.95% -60.24% -27.10% -13.73% 47.77% 118.30% 1,071.15% -91.69%
Invested Capital Growth		 -53.06% 127.25% 8,304.18% 6.57% 103.55% 54.43% 48.43% 13.81% 2.39% 45.73% 44.18%
Revenue Q/Q Growth		 171.82% 2.61% 0.12% -31.87% 37.35% 4.76% 18.14% 18.09% 10.21% 11.40% 4.42%
EBITDA Q/Q Growth		 28.54% 14.20% -62.80% -13.30% 25.24% -17.64% 7.76% 19.14% 188.84% 18.89% 14.02%
EBIT Q/Q Growth		 27.41% 13.11% -63.41% -11.24% 22.31% -16.68% 6.35% 14.60% 2,879.15% 21.02% 14.69%
NOPAT Q/Q Growth		 27.22% 13.09% -63.37% -11.06% 17.39% -16.92% 6.46% 15.34% 1,513.68% 90.21% -31.42%
Net Income Q/Q Growth		 22.46% 11.14% -63.97% -8.33% 13.41% -13.22% 3.71% 6.28% -23.71% 190.13% -29.85%
EPS Q/Q Growth		 -3.59% 5.85% 4.02% -9.02% 19.09% -3.53% 20.31% 5.71% -30.00% 189.29% -29.41%
Operating Cash Flow Q/Q Growth		 -8.26% 2.48% -35.40% -9.49% -1.14% -14.05% -1.12% 30.48% 154.40% 37.91% -22.44%
Free Cash Flow Firm Q/Q Growth		 27.08% 4.85% -36.42% -5.97% 1.46% -16.37% -9.64% 37.99% 191.26% 30.64% -65.94%
Invested Capital Q/Q Growth		 9.01% 157.13% 26.66% 18.59% 15.88% 15.87% 18.24% 0.69% -2.20% 27.96% 4.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 39.93% 40.34% -28.14% -148.42% -34.60% -45.17% 1.45% 22.89% 34.44% 51.48% 57.39%
EBITDA Margin		 -204.94% -153.10% -158.12% -329.75% -88.00% -140.84% -63.47% -19.88% 12.44% 34.62% 39.18%
Operating Margin		 -216.14% -162.56% -172.71% -354.95% -141.14% -153.75% -72.12% -25.55% 8.38% 32.59% 37.53%
EBIT Margin		 -215.20% -162.52% -172.76% -355.70% -102.64% -154.06% -72.43% -25.96% 8.27% 32.55% 37.48%
Profit (Net Income) Margin		 -250.36% -183.05% -192.26% -387.06% -164.50% -179.41% -88.52% -42.77% -10.94% 46.35% 28.80%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 157.24% 80.44%
Interest Burden Percent		 116.34% 112.64% 111.29% 108.82% 160.27% 116.46% 122.21% 164.76% -132.30% 90.58% 95.52%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.24% 19.56%
Return on Invested Capital (ROIC)		 0.00% 0.00% -140.55% -105.59% -46.33% -42.55% -25.38% -13.40% 6.83% 79.32% 38.60%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -1,130.62% -342.99% -95.01% -103.70% -91.85% -78.25% -48.77% 16.83% 88.30%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -103.40% -113.18% -163.75% -89.83% -37.08% -31.57% -26.50% 2.32% -3.04%
Return on Equity (ROE)		 -526.23% 1,073.36% -243.95% -218.77% -210.08% -132.38% -62.46% -44.96% -19.67% 81.65% 35.56%
Cash Return on Invested Capital (CROIC)		 0.00% -3,101.67% -335.85% -111.95% -114.55% -85.34% -64.37% -26.32% 4.47% 42.10% 2.42%
Operating Return on Assets (OROA)		 -60.89% -73.11% -59.71% -61.37% -27.90% -38.86% -24.23% -12.81% 6.30% 33.94% 34.37%
Return on Assets (ROA)		 -70.83% -82.34% -66.45% -66.78% -44.71% -45.25% -29.61% -21.10% -8.33% 48.34% 26.40%
Return on Common Equity (ROCE)		 -526.23% 1,073.36% -243.94% -218.77% -210.08% -132.38% -62.46% -44.96% -19.67% 81.65% 35.56%
Return on Equity Simple (ROE_SIMPLE)		 -2,188.85% 437.83% -108.49% -332.53% -184.32% -85.83% -50.75% -43.37% -20.89% 56.64% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -12 -28 -42 -29 -45 -41 -28 15 219 154
NOPAT Margin		 -151.30% -113.79% -120.90% -248.46% -98.80% -107.63% -50.48% -17.88% 5.86% 51.25% 30.19%
Net Nonoperating Expense Percent (NNEP)		 -147.78% 613.49% 990.07% 237.40% 48.68% 61.15% 66.48% 64.86% 55.60% 62.49% -49.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -9.02% 5.49% 50.83% 27.69%
Cost of Revenue to Revenue		 60.07% 59.66% 128.14% 248.42% 134.60% 145.17% 98.55% 77.11% 65.56% 48.52% 42.61%
SG&A Expenses to Revenue		 158.33% 130.78% 110.96% 178.44% 95.68% 92.90% 68.18% 45.63% 24.51% 18.38% 18.90%
R&D to Revenue		 97.75% 72.12% 24.47% 23.11% 7.99% 13.99% 4.50% 2.35% 1.28% 0.43% 0.93%
Operating Expenses to Revenue		 256.07% 202.89% 144.58% 206.53% 106.54% 108.58% 73.57% 48.44% 26.07% 18.89% 19.86%
Earnings before Interest and Taxes (EBIT)		 -15 -17 -39 -60 -30 -65 -59 -40 21 139 191
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -16 -36 -56 -26 -59 -51 -31 32 148 200
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 105.31 0.00 2.05 5.60 9.06 2.09 1.96 5.02 7.55 11.62 0.00
Price to Tangible Book Value (P/TBV)		 105.31 0.00 2.59 9.05 12.17 2.24 2.03 5.18 7.79 11.75 0.00
Price to Revenue (P/Rev)		 12.05 6.19 3.64 6.52 8.08 4.37 3.41 4.96 3.96 9.51 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.51 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.88% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 153.98 2.10 3.21 3.51 1.74 1.70 3.79 4.95 12.34 0.00
Enterprise Value to Revenue (EV/Rev)		 11.70 6.65 3.57 7.79 10.05 5.35 4.04 5.39 4.30 9.45 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 34.56 27.31 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.02 29.05 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73.33 18.45 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 126.18 33.97 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 112.11 34.76 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 17.42 -4.54 1.07 2.24 3.23 1.10 0.72 1.01 1.04 0.23 0.17
Long-Term Debt to Equity		 17.40 -3.17 1.07 2.24 3.23 1.10 0.72 1.01 1.04 0.23 0.16
Financial Leverage		 -1.41 -0.66 0.09 0.33 1.72 0.87 0.40 0.40 0.54 0.14 -0.03
Leverage Ratio		 7.43 -13.04 3.67 3.28 4.70 2.93 2.11 2.13 2.36 1.69 1.35
Compound Leverage Factor		 8.64 -14.68 4.09 3.56 7.53 3.41 2.58 3.51 -3.12 1.53 1.29
Debt to Total Capital		 94.57% 128.27% 51.58% 69.11% 76.34% 52.44% 42.02% 50.26% 50.94% 18.82% 14.17%
Short-Term Debt to Total Capital		 0.10% 38.76% 0.00% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.51%
Long-Term Debt to Total Capital		 94.47% 89.51% 51.58% 69.06% 76.34% 52.44% 42.02% 50.26% 50.94% 18.82% 13.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 5.43% -28.27% 48.42% 30.89% 23.66% 47.56% 57.98% 49.74% 49.06% 81.18% 85.83%
Debt to EBITDA		 -0.97 -1.24 -1.19 -0.79 -3.27 -1.64 -1.99 -5.01 4.37 0.55 0.39
Net Debt to EBITDA		 0.17 -0.30 0.05 -0.38 -2.24 -0.70 -1.00 -2.19 2.77 -0.15 -0.04
Long-Term Debt to EBITDA		 -0.97 -0.86 -1.19 -0.79 -3.27 -1.64 -1.99 -5.01 4.37 0.55 0.38
Debt to NOPAT		 -1.32 -1.67 -1.56 -1.05 -2.91 -2.14 -2.50 -5.57 9.27 0.37 0.51
Net Debt to NOPAT		 0.23 -0.41 0.06 -0.51 -1.99 -0.91 -1.25 -2.43 5.88 -0.10 -0.06
Long-Term Debt to NOPAT		 -1.32 -1.16 -1.56 -1.05 -2.91 -2.14 -2.50 -5.57 9.27 0.37 0.49
Altman Z-Score		 -3.88 -6.35 -1.62 -4.03 -1.38 -1.43 -0.49 1.27 2.76 19.02 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.05 1.93 6.60 4.63 6.12 7.71 6.87 6.89 5.16 5.97 6.71
Quick Ratio		 4.21 1.45 4.98 2.51 2.15 3.47 2.62 2.60 1.58 2.76 3.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -14 -66 -45 -72 -91 -104 -54 9.90 116 9.64
Operating Cash Flow to CapEx		 -59,135.52% -24,886.22% -1,392.65% -2,990.97% -1,998.87% -801.62% -831.69% -427.78% 184.45% 1,442.65% 223.24%
Free Cash Flow to Firm to Interest Expense		 -4.01 -6.38 -14.62 -8.10 -3.78 -8.29 -7.94 -2.09 0.19 7.64 0.92
Operating Cash Flow to Interest Expense		 -6.02 -8.16 -8.29 -11.35 -4.02 -9.28 -8.61 -2.29 0.17 7.82 4.82
Operating Cash Flow Less CapEx to Interest Expense		 -6.03 -8.19 -8.89 -11.73 -4.22 -10.44 -9.64 -2.83 0.08 7.28 2.66
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.28 0.45 0.35 0.17 0.27 0.25 0.33 0.49 0.76 1.04 0.92
Accounts Receivable Turnover		 10.97 10.98 9.29 6.44 12.07 5.05 3.87 6.99 12.03 11.02 4.90
Inventory Turnover		 1.67 1.50 3.31 2.70 1.10 0.91 0.77 0.83 1.01 1.21 1.15
Fixed Asset Turnover		 2.74 4.85 1.40 0.56 0.95 1.15 1.75 2.82 4.61 7.86 8.52
Accounts Payable Turnover		 2.23 2.73 6.87 7.14 5.24 6.05 6.79 9.26 11.72 11.53 10.17
Days Sales Outstanding (DSO)		 33.27 33.25 39.27 56.65 30.24 72.22 94.28 52.21 30.34 33.13 74.56
Days Inventory Outstanding (DIO)		 218.19 242.90 110.44 135.14 331.15 400.78 471.89 442.37 362.46 302.67 316.22
Days Payable Outstanding (DPO)		 163.69 133.49 53.10 51.13 69.64 60.29 53.77 39.41 31.15 31.65 35.88
Cash Conversion Cycle (CCC)		 87.77 142.66 96.61 140.66 291.74 412.71 512.39 455.18 361.65 304.16 354.90
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.69 0.46 39 41 84 130 192 219 224 327 471
Invested Capital Turnover		 -5.14 -17.35 1.16 0.43 0.47 0.40 0.50 0.75 1.17 1.55 1.28
Increase / (Decrease) in Invested Capital		 -0.59 2.15 38 2.54 43 46 63 27 5.24 103 144
Enterprise Value (EV)		 84 71 81 132 295 226 327 831 1,110 4,032 0.00
Market Capitalization		 86 66 83 111 237 184 276 763 1,021 4,054 0.00
Book Value per Share		 $0.08 ($0.35) $1.56 $0.43 $0.44 $0.93 $0.72 $0.77 $0.60 $1.48 $2.00
Tangible Book Value per Share		 $0.08 ($0.35) $1.24 $0.26 $0.33 $0.87 $0.69 $0.75 $0.58 $1.46 $1.99
Total Capital		 15 16 83 64 111 186 244 306 276 430 556
Total Debt		 14 20 43 44 85 97 102 154 140 81 79
Total Long-Term Debt		 14 14 43 44 85 97 102 154 140 81 76
Net Debt		 -2.51 4.92 -1.64 21 58 41 51 67 89 -22 -8.84
Capital Expenditures (CapEx)		 0.03 0.07 2.68 2.10 3.81 13 14 14 4.77 8.23 23
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.28 1.24 8.29 12 45 78 127 145 156 173 312
Debt-free Net Working Capital (DFNWC)		 17 17 53 35 72 134 178 231 207 276 400
Net Working Capital (NWC)		 17 10 53 35 72 134 178 231 207 276 397
Net Nonoperating Expense (NNE)		 7.11 7.38 16 24 19 30 31 38 43 21 7.07
Net Nonoperating Obligations (NNO)		 -2.51 4.92 -1.64 21 58 41 51 67 89 -22 -6.19
Total Depreciation and Amortization (D&A)		 0.74 1.00 3.33 4.41 4.30 5.58 7.25 9.37 11 8.85 8.67
Debt-free, Cash-free Net Working Capital to Revenue		 3.90% 11.63% 36.44% 71.71% 153.46% 184.44% 157.22% 93.86% 60.36% 40.50% 61.19%
Debt-free Net Working Capital to Revenue		 238.09% 155.19% 232.43% 205.68% 244.62% 316.90% 220.34% 150.01% 80.25% 64.69% 78.36%
Net Working Capital to Revenue		 237.88% 97.87% 232.43% 205.50% 244.62% 316.90% 220.34% 150.01% 80.25% 64.69% 77.81%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.73) ($1.61) ($1.91) ($1.45) ($0.89) ($0.88) ($0.51) ($0.33) ($0.13) $0.85 $0.62
Adjusted Weighted Average Basic Shares Outstanding		 10.71M 12.89M 45.32M 46.35M 86.35M 121.28M 139.58M 197.87M 223.98M 233.08M 238.30M
Adjusted Diluted Earnings per Share		 ($1.73) ($1.61) ($1.91) ($1.45) ($0.89) ($0.88) ($0.51) ($0.33) ($0.13) $0.81 $0.60
Adjusted Weighted Average Diluted Shares Outstanding		 10.71M 12.89M 45.32M 46.35M 86.35M 121.28M 139.58M 197.87M 223.98M 243.34M 244.90M
Adjusted Basic & Diluted Earnings per Share		 ($1.73) ($1.61) ($1.91) ($1.45) ($0.89) ($0.88) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.41M 12.15M 22.90M 45.19M 54.35M 86.15M 195.92M 222.16M 228.22M 237.62M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -12 -27 -42 -29 -45 -41 -28 15 97 154
Normalized NOPAT Margin		 -151.30% -113.79% -118.30% -248.46% -98.80% -107.63% -50.48% -17.88% 5.86% 22.81% 30.19%
Pre Tax Income Margin		 -250.36% -183.05% -192.26% -387.06% -164.50% -179.41% -88.52% -42.77% -10.94% 29.48% 35.80%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.03 -7.74 -8.75 -10.94 -1.59 -5.92 -4.49 -1.54 0.42 9.15 18.31
NOPAT to Interest Expense		 -4.24 -5.42 -6.12 -7.64 -1.53 -4.13 -3.13 -1.06 0.30 14.40 14.74
EBIT Less CapEx to Interest Expense		 -6.04 -7.77 -9.34 -11.32 -1.79 -7.07 -5.52 -2.08 0.32 8.61 16.15
NOPAT Less CapEx to Interest Expense		 -4.25 -5.45 -6.72 -8.02 -1.73 -5.29 -4.16 -1.60 0.20 13.86 12.58
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.74%

Quarterly Metrics And Ratios for ADMA Biologics

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 237,615,100.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 237,615,100.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 63.73% 47.86% 43.86% 78.29% 78.13% 59.06% 40.22% 13.80% 12.00% 18.39% -0.27%
EBITDA Growth		 273.60% 511.94% 1,366.08% 1,729.68% 268.81% 138.81% 53.17% 8.33% 27.34% 60.89% 62.77%
EBIT Growth		 191.57% 317.48% 2,693.57% 8,162.76% 363.49% 170.59% 59.81% 8.94% 28.82% 64.06% 66.97%
NOPAT Growth		 233.17% 334.93% 3,810.32% 10,688.33% 345.96% 1,139.90% 32.86% 4.18% 0.97% -59.28% 64.81%
Net Income Growth		 117.22% -44.25% 362.28% 603.25% 1,299.96% 734.19% 51.10% 6.73% 1.45% -55.87% 68.48%
EPS Growth		 112.50% -60.00% 366.67% 533.33% 1,400.00% 662.50% 37.50% 7.69% 0.00% -55.56% 72.73%
Operating Cash Flow Growth		 190.22% 338.47% 84.94% 853.36% 108.83% 185.37% -787.06% -53.69% -46.89% -29.03% 396.06%
Free Cash Flow Firm Growth		 94.93% 115.33% 112.63% 231.69% 506.62% 344.24% -3,024.08% -485.43% -1,344.29% -548.05% 74.92%
Invested Capital Growth		 5.42% 2.39% 7.57% 2.34% 11.39% 45.73% 53.84% 62.62% 76.85% 44.18% 19.02%
Revenue Q/Q Growth		 11.90% 9.85% 10.79% 30.92% 11.80% -1.91% -2.34% 6.26% 10.03% 3.68% -17.73%
EBITDA Q/Q Growth		 399.87% 49.35% 42.68% 71.76% 0.76% -3.29% -8.48% 21.48% 18.44% 22.19% -7.41%
EBIT Q/Q Growth		 1,857.20% 65.47% 54.16% 79.86% 1.01% -3.40% -8.94% 22.61% 19.44% 23.03% -7.33%
NOPAT Q/Q Growth		 2,723.07% 14.72% 111.94% 66.03% 10.48% 218.94% -77.29% 30.19% 7.08% 28.63% -8.09%
Net Income Q/Q Growth		 140.26% -787.88% 200.92% 80.06% 12.00% 211.61% -75.96% 27.19% 6.46% 35.55% -8.20%
EPS Q/Q Growth		 133.33% -900.00% 200.00% 62.50% 15.38% 200.00% -75.56% 27.27% 7.14% 33.33% -5.00%
Operating Cash Flow Q/Q Growth		 297.80% 46.83% -112.61% 2,157.98% -45.17% 100.64% -139.18% 207.44% -37.12% 168.10% 63.44%
Free Cash Flow Firm Q/Q Growth		 86.16% 252.13% -23.39% 716.60% -57.28% 66.21% -604.27% -7.64% -37.93% 40.15% 71.78%
Invested Capital Q/Q Growth		 -2.35% -2.20% 10.92% -3.39% 6.28% 27.96% 17.09% 2.12% 15.58% 4.32% -3.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 36.65% 42.06% 47.77% 53.60% 49.78% 53.88% 53.22% 55.11% 56.34% 63.82% 70.53%
EBITDA Margin		 16.82% 22.87% 29.46% 38.65% 34.83% 34.34% 32.18% 36.79% 39.60% 46.66% 52.52%
Operating Margin		 12.91% 19.26% 26.65% 36.57% 33.08% 32.60% 30.38% 35.08% 38.01% 45.09% 50.90%
EBIT Margin		 12.69% 19.12% 26.61% 36.56% 33.03% 32.53% 30.33% 35.00% 37.99% 45.08% 50.78%
Profit (Net Income) Margin		 3.81% -23.87% 21.75% 29.91% 29.96% 95.19% 23.44% 28.05% 27.14% 35.48% 39.59%
Tax Burden Percent		 100.00% 100.00% 96.77% 89.43% 97.71% 322.35% 80.43% 85.34% 76.67% 80.17% 79.35%
Interest Burden Percent		 30.04% -124.86% 84.46% 91.49% 92.84% 90.78% 96.07% 93.93% 93.18% 98.18% 98.27%
Effective Tax Rate		 0.00% 0.00% 3.23% 10.57% 2.29% -222.35% 19.57% 14.66% 23.33% 19.83% 20.65%
Return on Invested Capital (ROIC)		 13.54% 15.71% 30.43% 45.47% 51.06% 162.67% 35.56% 45.00% 40.27% 46.23% 49.14%
ROIC Less NNEP Spread (ROIC-NNEP)		 7.26% -19.68% 26.77% 41.19% 45.48% 127.82% 33.35% 34.62% 28.06% 52.76% 46.69%
Return on Net Nonoperating Assets (RNNOA)		 5.62% -10.69% 16.15% 17.22% 12.02% 17.63% 6.59% 2.62% 1.86% -1.82% 4.54%
Return on Equity (ROE)		 19.16% 5.02% 46.58% 62.69% 63.08% 180.30% 42.16% 47.62% 42.13% 44.41% 53.68%
Cash Return on Invested Capital (CROIC)		 -4.86% 4.47% 5.62% 33.02% 36.64% 42.10% 28.33% 23.39% 8.01% 2.42% 23.72%
Operating Return on Assets (OROA)		 9.16% 14.57% 21.79% 33.56% 34.19% 33.92% 32.35% 35.50% 38.69% 41.33% 44.04%
Return on Assets (ROA)		 2.75% -18.19% 17.81% 27.46% 31.02% 99.27% 24.99% 28.46% 27.64% 32.53% 34.34%
Return on Common Equity (ROCE)		 19.16% 5.02% 46.58% 62.69% 63.08% 180.30% 42.16% 47.62% 42.13% 44.41% 53.68%
Return on Equity Simple (ROE_SIMPLE)		 -15.07% 0.00% -2.37% 18.48% 29.38% 0.00% 55.37% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 8.69 9.96 21 35 39 124 28 37 39 50 46
NOPAT Margin		 12.91% 13.48% 25.79% 32.71% 32.32% 105.09% 24.44% 29.94% 29.14% 36.15% 40.39%
Net Nonoperating Expense Percent (NNEP)		 6.28% 35.39% 3.67% 4.28% 5.57% 34.86% 2.21% 10.38% 12.21% -6.53% 2.45%
Return On Investment Capital (ROIC_SIMPLE)		 - 3.62% - - - 28.73% 6.18% 7.59% 7.62% 9.05% 7.79%
Cost of Revenue to Revenue		 63.35% 57.94% 52.23% 46.40% 50.22% 46.12% 46.78% 44.89% 43.66% 36.18% 29.47%
SG&A Expenses to Revenue		 22.58% 21.95% 20.33% 16.37% 16.34% 20.92% 22.09% 19.16% 17.17% 17.70% 24.28%
R&D to Revenue		 0.89% 0.60% 0.55% 0.52% 0.34% 0.33% 0.72% 0.85% 1.14% 0.99% 2.27%
Operating Expenses to Revenue		 23.74% 22.80% 21.11% 17.03% 16.71% 21.28% 22.84% 20.03% 18.34% 18.73% 26.60%
Earnings before Interest and Taxes (EBIT)		 8.54 14 22 39 40 38 35 43 51 63 58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11 17 24 41 42 40 37 45 53 65 60
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.32 7.55 9.70 13.77 20.09 11.62 12.62 10.86 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 5.46 7.79 9.95 14.07 20.45 11.75 12.76 10.97 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.44 3.96 5.27 7.85 12.17 9.51 10.26 9.13 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 74.50 68.39 20.51 22.80 20.71 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 1.34% 1.46% 4.88% 4.39% 4.83% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.85 4.95 6.38 11.00 18.34 12.34 12.35 11.05 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.77 4.30 5.60 8.01 12.23 9.45 10.28 9.11 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 79.39 34.56 29.05 28.20 37.71 27.31 29.44 26.35 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 1,232.41 52.02 36.08 31.61 40.83 29.05 31.11 27.81 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 940.99 73.33 51.20 31.49 40.76 18.45 21.15 19.26 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 126.18 74.46 36.21 54.42 33.97 46.67 56.31 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 112.11 117.59 33.70 52.74 34.76 52.81 58.54 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.00 1.04 0.91 0.75 0.48 0.23 0.22 0.21 0.19 0.17 0.52
Long-Term Debt to Equity		 1.00 1.04 0.91 0.75 0.48 0.23 0.22 0.21 0.18 0.16 0.51
Financial Leverage		 0.77 0.54 0.60 0.42 0.26 0.14 0.20 0.08 0.07 -0.03 0.10
Leverage Ratio		 2.58 2.36 2.31 2.15 1.93 1.69 1.63 1.59 1.45 1.35 1.54
Compound Leverage Factor		 0.77 -2.95 1.95 1.96 1.79 1.53 1.57 1.50 1.35 1.32 1.51
Debt to Total Capital		 50.09% 50.94% 47.73% 42.69% 32.21% 18.82% 17.79% 17.19% 15.95% 14.17% 34.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.51% 0.55%
Long-Term Debt to Total Capital		 50.09% 50.94% 47.73% 42.69% 32.21% 18.82% 17.79% 17.19% 15.49% 13.66% 33.69%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 49.91% 49.06% 52.27% 57.31% 67.79% 81.18% 82.21% 82.81% 84.05% 85.83% 65.76%
Debt to EBITDA		 13.66 4.37 2.57 1.50 0.89 0.55 0.50 0.50 0.47 0.39 0.91
Net Debt to EBITDA		 7.00 2.77 1.74 0.55 0.19 -0.15 0.06 -0.05 0.12 -0.04 0.29
Long-Term Debt to EBITDA		 13.66 4.37 2.57 1.50 0.89 0.55 0.50 0.50 0.45 0.38 0.90
Debt to NOPAT		 161.97 9.27 4.53 1.67 0.96 0.37 0.36 0.37 0.36 0.51 1.18
Net Debt to NOPAT		 82.95 5.88 3.07 0.62 0.20 -0.10 0.04 -0.03 0.09 -0.06 0.38
Long-Term Debt to NOPAT		 161.97 9.27 4.53 1.67 0.96 0.37 0.36 0.37 0.35 0.49 1.16
Altman Z-Score		 2.03 2.69 4.37 8.62 18.26 18.34 21.68 17.40 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.54 5.16 5.21 6.87 7.09 5.97 6.58 5.33 7.13 6.71 6.95
Quick Ratio		 2.52 1.58 1.79 2.68 3.05 2.76 3.20 2.67 3.52 3.54 3.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.11 4.73 3.62 30 13 21 -106 -114 -157 -94 -27
Operating Cash Flow to CapEx		 1,583.22% 1,470.09% -94.50% 2,209.39% 2,370.08% 1,821.40% -418.53% 872.79% 92.52% 3,287.73% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.49 0.15 0.96 7.81 3.61 5.09 -53.59 -38.07 -40.80 -57.84 -12.64
Operating Cash Flow to Interest Expense		 1.87 0.54 -0.59 12.07 7.15 12.18 -9.96 7.06 3.45 21.92 27.74
Operating Cash Flow Less CapEx to Interest Expense		 1.75 0.51 -1.21 11.52 6.85 11.51 -12.34 6.25 -0.28 21.25 28.91
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.72 0.76 0.82 0.92 1.04 1.04 1.07 1.01 1.02 0.92 0.87
Accounts Receivable Turnover		 8.97 12.03 7.44 9.88 9.40 11.02 6.16 6.78 5.20 4.90 4.33
Inventory Turnover		 1.00 1.01 1.00 1.04 1.17 1.21 1.25 1.20 1.20 1.15 1.00
Fixed Asset Turnover		 4.19 4.61 5.03 5.97 7.06 7.86 8.13 8.48 7.93 8.52 8.31
Accounts Payable Turnover		 9.00 11.72 11.39 13.55 14.55 11.53 11.53 10.14 11.05 10.17 9.60
Days Sales Outstanding (DSO)		 40.68 30.34 49.07 36.94 38.83 33.13 59.21 53.82 70.16 74.56 84.21
Days Inventory Outstanding (DIO)		 366.70 362.46 363.34 350.34 312.64 302.67 293.15 304.04 303.90 316.22 364.44
Days Payable Outstanding (DPO)		 40.55 31.15 32.05 26.94 25.08 31.65 31.66 35.99 33.02 35.88 38.02
Cash Conversion Cycle (CCC)		 366.83 361.65 380.36 360.34 326.39 304.16 320.70 321.87 341.03 354.90 410.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 229 224 249 240 255 327 383 391 452 471 455
Invested Capital Turnover		 1.05 1.17 1.18 1.39 1.58 1.55 1.46 1.50 1.38 1.28 1.22
Increase / (Decrease) in Invested Capital		 12 5.24 17 5.50 26 103 134 150 196 144 73
Enterprise Value (EV)		 883 1,110 1,586 2,644 4,683 4,032 4,723 4,319 0.00 0.00 0.00
Market Capitalization		 805 1,021 1,491 2,592 4,659 4,054 4,714 4,327 0.00 0.00 0.00
Book Value per Share		 $0.67 $0.60 $0.67 $0.81 $0.99 $1.48 $1.57 $1.65 $1.81 $2.00 $1.65
Tangible Book Value per Share		 $0.66 $0.58 $0.65 $0.79 $0.98 $1.46 $1.55 $1.63 $1.79 $1.99 $1.64
Total Capital		 303 276 294 329 342 430 454 481 513 556 594
Total Debt		 152 140 140 140 110 81 81 83 82 79 203
Total Long-Term Debt		 152 140 140 140 110 81 81 83 79 76 200
Net Debt		 78 89 95 52 23 -22 9.20 -7.59 20 -8.84 65
Capital Expenditures (CapEx)		 0.76 1.20 2.35 2.07 1.06 2.76 4.70 2.42 14 1.08 -2.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 158 156 178 171 187 173 227 234 287 312 303
Debt-free Net Working Capital (DFNWC)		 232 207 223 260 273 276 298 325 349 400 441
Net Working Capital (NWC)		 232 207 223 260 273 276 298 325 346 397 438
Net Nonoperating Expense (NNE)		 6.12 28 3.31 3.00 2.82 12 1.15 2.31 2.68 0.93 0.91
Net Nonoperating Obligations (NNO)		 78 89 95 52 23 -22 9.20 -7.59 20 -6.19 65
Total Depreciation and Amortization (D&A)		 2.78 2.77 2.33 2.24 2.16 2.13 2.12 2.18 2.16 2.21 1.99
Debt-free, Cash-free Net Working Capital to Revenue		 67.31% 60.36% 62.86% 51.86% 48.74% 40.50% 49.35% 49.42% 58.77% 61.19% 59.38%
Debt-free Net Working Capital to Revenue		 98.96% 80.25% 78.87% 78.58% 71.39% 64.69% 64.94% 68.46% 71.33% 78.36% 86.48%
Net Working Capital to Revenue		 98.96% 80.25% 78.87% 78.58% 71.39% 64.69% 64.94% 68.46% 70.85% 77.81% 85.83%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.01 ($0.08) $0.08 $0.14 $0.15 $0.48 $0.11 $0.14 $0.15 $0.22 $0.19
Adjusted Weighted Average Basic Shares Outstanding		 225.28M 223.98M 228.87M 232.42M 234.57M 233.08M 237.78M 241.49M 238.60M 238.30M 236.07M
Adjusted Diluted Earnings per Share		 $0.01 ($0.08) $0.08 $0.13 $0.15 $0.45 $0.11 $0.14 $0.15 $0.20 $0.19
Adjusted Weighted Average Diluted Shares Outstanding		 233.76M 223.98M 236.41M 242.17M 244.80M 243.34M 244.68M 248.61M 244.66M 244.90M 239.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 225.97M 228.22M 231.81M 233.08M 236.39M 237.62M 0.00 0.00 0.00 0.00 231.77M
Normalized Net Operating Profit after Tax (NOPAT)		 6.08 9.96 21 35 39 27 28 37 39 50 46
Normalized NOPAT Margin		 9.04% 13.48% 25.79% 32.71% 32.32% 22.82% 24.44% 29.94% 29.14% 36.15% 40.39%
Pre Tax Income Margin		 3.81% -23.87% 22.47% 33.45% 30.67% 29.53% 29.14% 32.87% 35.40% 44.26% 49.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.33 0.44 5.78 10.36 11.31 9.28 17.63 14.26 13.24 38.58 27.68
NOPAT to Interest Expense		 1.36 0.31 5.60 9.27 11.07 29.97 14.21 12.20 10.15 30.94 22.02
EBIT Less CapEx to Interest Expense		 1.22 0.40 5.16 9.81 11.01 8.61 15.25 13.45 9.51 37.91 28.85
NOPAT Less CapEx to Interest Expense		 1.24 0.27 4.98 8.72 10.77 29.30 11.82 11.39 6.42 30.27 23.19
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.74% 98.05%

Financials Breakdown Chart

Key Financial Trends

ADMA Biologics has delivered a strong turnaround over the last several years, with revenue, profitability, and operating cash flow all improving meaningfully. The latest Q1 2026 results show that the company remains profitable and well-capitalized, although it also carries a sizable debt load and continues to see working-capital swings tied to inventory and receivables.

  • Revenue continues to grow. Q1 2026 revenue was $114.5 million, up from $81.9 million in Q1 2024 and above the $114.8 million reported in Q1 2025.
  • Profitability remains solid. Q1 2026 net income was $45.3 million, compared with $17.8 million in Q1 2024 and $26.9 million in Q1 2025.
  • Gross profit has expanded significantly over the past year. In Q1 2026, gross profit reached $80.8 million, reflecting continued operating leverage.
  • Operating income is strong. Q1 2026 operating income of $58.3 million shows the core business is generating healthy earnings before interest and taxes.
  • Operating cash flow turned sharply positive. Q1 2026 cash from operations was $58.2 million, versus a negative $19.7 million in Q1 2025 and negative $2.2 million in Q1 2024.
  • Liquidity improved. Cash and equivalents rose to $138.2 million in Q1 2026 from $61.4 million in Q3 2025 and $71.6 million in Q1 2025.
  • Book equity increased. Total common equity was $390.3 million in Q1 2026, up from $373.4 million in Q1 2025 and $231.9 million in Q3 2025.
  • Longer-term earnings trend is encouraging. The company moved from losses in early 2023 to consistent quarterly profits through 2024 and 2025, suggesting a durable operating improvement.
  • Inventory remains very large. Inventory was $222.1 million in Q1 2026, meaning a significant portion of current assets is tied up in stock.
  • Accounts receivable also remains elevated. Receivables were $135.9 million, so a meaningful amount of revenue is still sitting on the balance sheet waiting to be collected.
  • Capital spending continues. The company spent $2.5 million on PP&E in Q1 2026, which is modest but still reflects ongoing investment needs.
  • Debt is still substantial. Q1 2026 long-term debt was $193.6 million, plus $3.3 million of short-term debt and $6.4 million of capital lease obligations.
  • Interest expense remains meaningful. Q1 2026 interest expense was $2.1 million, which continues to reduce pre-tax earnings.
  • Working-capital swings can be volatile. Cash flow benefited from changes in operating assets and liabilities in Q1 2026, but those items have been highly uneven across prior quarters.
  • Q1 2025 was a reminder that cash flow can swing negative. Operating cash flow was -$19.7 million in that quarter, showing the business is not immune to short-term volatility.

Bottom line: ADMA Biologics looks fundamentally stronger than it did two years ago. Revenue is rising, margins are robust, and the business is now generating substantial operating cash flow. The main items investors should monitor are leverage, inventory levels, and whether the company can keep converting sales into cash consistently.

06/15/26 08:20 PM ETAI Generated. May Contain Errors.

ADMA Biologics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ADMA Biologics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ADMA Biologics' net income appears to be on a downward trend, with a most recent value of $146.93 million in 2025, falling from -$17.97 million in 2015. The previous period was $197.67 million in 2024. Find out what analysts predict for ADMA Biologics in the coming months.

ADMA Biologics' total operating income in 2025 was $191.44 million, based on the following breakdown:
  • Total Gross Profit: $292.77 million
  • Total Operating Expenses: $101.32 million

Over the last 10 years, ADMA Biologics' total revenue changed from $7.18 million in 2015 to $510.17 million in 2025, a change of 7,007.8%.

ADMA Biologics' total liabilities were at $146.92 million at the end of 2025, a 5.2% increase from 2024, and a 541.8% increase since 2015.

In the past 10 years, ADMA Biologics' cash and equivalents has ranged from $9.91 million in 2016 to $103.15 million in 2024, and is currently $87.63 million as of their latest financial filing in 2025.

Over the last 10 years, ADMA Biologics' book value per share changed from 0.08 in 2015 to 2.00 in 2025, a change of 2,514.9%.


Related Companies

Financial statements for NASDAQ:ADMA last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel